Background {#Sec1}
==========

ApoM gene coded for a 26 kDa protein and located on chromosome 6q21--q23 which was a high susceptibility region to T2DM in genome-wide linkage analyses \[[@CR1]--[@CR3]\]. It was mainly present in high density lipoprotein cholesterol (HDL-C) and lesser extent in low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), and chylomicrons \[[@CR1], [@CR4]\]. ApoM was the carrier of the biologically active lipid mediator sphingosine-1-phospate in HDL-C, played a critical role in formation and maturation of prebeta-HDL-C particles which could promote intracellular cholesterol efflux \[[@CR5]--[@CR7]\]. Several studies have identified promoter variants of apoM were associated with CAD and T2DM. Xu et al. have reported that the allele C carries of apoM rs9404941 (T-855C) polymorphism have an increased risk for CAD in Chinese populations \[[@CR8]\]. Wu et al. and Zhou et al. have found that apoM rs805296 (T-778C) polymorphism was significantly associated with type 1 diabetes mellitus (T1DM) and T2DM in northern chinese population \[[@CR9], [@CR10]\]. Studies on 17 SNPs of apoM showed that apoM SNPs rs805297 (C-1065A) was associated with T2DM duration and SNPs rs707922 (G-1837T) TT genotype significantly increased the total cholesterol (TC) and LDL levels in patients with T2DM \[[@CR11]\]. However, the genetic marker was distinct in different area such as northern and southern of China \[[@CR12], [@CR13]\], so the relationship between apoM rs805296 (T-778C) and the susceptibility of T2DM was not found in the southern Chinese population \[[@CR11]\]. A new SNP C-724del, in the proximal promoter of apoM, was significantly associated with a higher risk for CAD and myocardial infarction, obviously decreased promoter activities and apoM expression in vitro \[[@CR14], [@CR15]\]. The primary aim of the present case-controls study was to investigate the effect of SNP C-724del on apoM expressions and its association with T2DM susceptibility in an eastern Han Chinese cohort.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Two hundred and fifty-nine patients (149 males and 110 females) who were diagnosed T2DM by the WHO criteria \[fasting glucose ≥7.0 mmol/L (126 mg/dL) or 2-h glucose ≥11.1 mmol/L (200 mg/dL)\] \[[@CR16]\]. Exclusion criteria were hematologic neoplastic, hepatic, thyroid, cardiac, autoimmune diseases or non diabetic kidney disease. Seventy-six age- and gender-matched healthy people (40 males and 36 females) who were good general health, no significant past medical history, and documented normal fasting blood glucose and glucose intolerance were selected as the controls group in the present study. All T2DM patients and healthy controls subjects were from the First Affiliated Yijishan hospital with Wannan Medical College. This protocol was approved by the Medical Ethics Committee of the WanNan Medical College in China, and all participants were provided written informed consent. Blood pressure was measured on the right arm in a sitting position after 15 min rest with a standard mercury sphygmomanometer. All participants had an overnight fast and patients did not take their usual medication and insulin before blood sampling.

Methods {#Sec4}
-------

Plasma creatinine (Cr), cystatin c (CYS-C), superoxide dismutase (SOD), glucose, lipid levels and concentrations of urinary albumin were determined with Hitachi 7600 biochemistry autoanalyzer (Hitachi, Tokyo, Japan). All above reagents were purchased from BeiJing LEADMAN BIOCHEMISTRY CO, LTD, China. HbA1c was measured by HPLC using a Bio-Rad Variant II analyzer (Bio-Rad Laboratories, Hercules, CA, USA). Plasma apoM concentrations were assayed using a commercial ELISA kit (Cloud-Clone Corp, Houston, TX, USA) according to the manufacturer's instructions. The concentrations of apoM in the calibrator was determined using a standard of known apoM concentration. All samples were diluted 1:5000 and analyzed in duplicate. The range of the standard curve was 0.312 \~ 20 ng/mL.

Amplifying DNA of apoM proximal promoter region including SNPs C724del by RT-PCR and amplicons sequencing {#Sec5}
---------------------------------------------------------------------------------------------------------

Detail sequence information of apoM and SNP ID number are publicly available (<http://www.ncbi.nlm.nih.gov/SNP>). According to the sequence, a pair of primers were designed by primer premier 5.0 software (Premier Company, Canada) as follows: forward primer: AGTCACTTGGTGCTATCC; reverse: primer: GTTGGTGTCAGGCAGAAT, and the total sequence was 580 bp. The primers were synthesized by Sangon Biotech Company (Shanghai, China). Operation of extracting DNA from peripheral blood sample of each subject should accord with the instructions from a commercial DNA extract Kit (TIANamp, Beijing, China). Taq DNA polymerase, dNTPs, Polymerase chain reaction (PCR) buffer, and MgCl~2~ were all included in TIANamp Taq PCR Mastermix Kit purchased from TIANamp (Beijing, China). PCR was performed as follows: less than 0.1 ug genomic DNA template, 12.5 ul 2 × Taq PCR Mastermix, 10 umol of each primer and add ddH~2~O to a final reaction volume of 25 μl. Thermal cycling was performed in Veriti® PCR Thermal cycler (Applied Biosystems, America). The cycling program consisted of 3 min of initial denaturation at 94 °C, followed by 30 cycles at 95 °C for 30 s (temperature transition rate 3.9 °C/s), 60 °C for 30 s (temperature transition rate 3.9 °C/s), and 72 °C for 30 s (temperature transition rate 3.9 °C/s). PCR products of DNA including SNPs rs805297 (C-1065A), rs9404941 (T-855C) and rs805296 (T-778C), C-724del were directly sequenced on an automatic sequencer from Applied Biosystems (Model 3730, BGI, Shanghai, China).

Statistical analysis {#Sec6}
--------------------

Continuous variables were provided as mean ± SD and categorical variables were expressed as percentages. Comparisons of the general characteristics between different genotypes in two groups were statistically evaluated with SPSS statistical package version 16.0 (Chicago, IL, USA). Comparisons of the genotype distributions between the two groups were tested by the linear-by-linear association Chi-squared analyses. Allele frequencies, Hardy-Weinberg equilibrium of genotype distributions, odds ratios (ORs) and 95 % confidence intervals (CIs) were estimated by the Chi-squared analyses. Analyses of linkage disequilibrium (LD) between SNPs were determined by calculating pair-wise D' and r2 statistics in unrelated individuals using the SHEsis software online (<http://analysis.bio-x.cn/myAnalysis.php>). Power calculations were performed by SAS software (power and sample size, version 3.1). Significance was established at a *P* value \< 0.05.

Results {#Sec7}
=======

General characteristics of T2DM patients and healthy controls {#Sec8}
-------------------------------------------------------------

Comparisons of the baseline characteristics and plasma parameters between T2DM patients (*n* = 259) and healthy controls (*n* = 76) are shown in Table [1](#Tab1){ref-type="table"}. There were no statistical difference in age and sex between T2DM patients and healthy controls (*p* = 0.940 and *p* = 0.450, respectively). Lower HDL-C, apolipoproteinAI (apoA-I), apoM (20.17 ± 10.03 ng/uL vs 24.48 ± 11.45 ng/uL, *p* = 0.004) were seen in T2DM patients compared with those in healthy control.Table 1Clinical characteristics of healthy control and T2DM patientsHealthy control\
*N* = 76T2DM\
*N* = 259*P*-valueN (male/femal)40/36149/1100.450AGE (yrs)56.24 ± 8.5956.33 ± 11.490.940SBP (mmHg)117.36 ± 12.79137.71 ± 20.89**0.000**DBP (mmHg)76.00 ± 7.7983.44 ± 11.40**0.000**Cr (umol/L)64.80 ± 14.6175.03 ± 31.73**0.000**CYS-C (mg/L)0.97 ± 0.211.17 ± 0.50**0.000**SOD (U/mL)106.70 ± 10.6982.01 ± 25.78**0.000**FPG (mmol/L)5.36 ± 0.369.45 ± 3.33**0.000**TC (mmol/L)4.26 ± 0.524.46 ± 1.22**0.038**TG (mmol/L)1.18 ± 0.422.19 ± 1.89**0.000**HDL-C (mmol/L)1.41 ± 0.201.21 ± 0.32**0.000**LDL-C (mmol/L)2.31 ± 0.412.53 ± 0.80**0.002**apoA-I (g/L)1.66 ± 0.261.29 ± 0.34**0.000**apoB (g/L)0.75 ± 0.180.90 ± 0.33**0.000**LP (a) (mg/L)131.51 ± 113.31157.07 ± 191.360.269apoM (ng/uL)24.48 ± 11.4520.17 ± 10.03**0.004**Data mean ± SD*N* number, *M* male, *F* female, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *Cr* creatinine, *CYS-C* cystatin c, *SOD* superoxide dismutase, *FBG* fasting blood glucose, *TG* triglycerides, *TC* total cholesterol, *LDL-C* low-density lipoprotein cholesterol, *HDL-C* high-density lipoprotein cholesterol, *apo* apolipoprotein, *LP (a)* Lipoprotein (a)

Allele frequencies and genotype distributions of apoM promoter in T2DM patients and healthy controls {#Sec9}
----------------------------------------------------------------------------------------------------

As showed in Table [2](#Tab2){ref-type="table"}, C-1065A, T-855C, T-778C and C-724del were found in the present study (Fig. [1](#Fig1){ref-type="fig"}). Genotype distributions of these four SNPs in T2DM patients and healthy controls followed Hardy-Weinberg equilibrium (HWE, *P* \> 0.05). C-1065A and T-855C showed no statistically significant difference in allele frequencies and genotype distributions between T2DM patients and healthy controls. Besides that, this study did not find the difference in allele frequencies and genotype distributions of SNP T-778C in these two groups. In T2DM patients, 212 patients (81.9 %) had the T/T genotype, 46 patients (17.8 %) had the T/C genotype and 1 patients (0.3 %) had the C/C genotype. While in healthy control, the rate were 73.7 %, 26.3 %, 0 %, respectively. The genotype distribution of SNP T-778C was not statistically different between T2DM patients and healthy controls (*P* = 0.146). The minor C allele frequency of SNP T-778C in the T2DM group was not significant different with healthy controls (9.3 % vs 13.2 %, *P* = 0.162). In SNP C-724del, the frequency of del allele was 6.4 % in T2DM patients and only 2.0 % in healthy controls (*P* = 0.035). In T2DM patients, 228 patients (88.0 %) had the C/C genotype, 29 patients (11.2 %) had the C /del genotype and 2 patients (0.8 %) had the del/del genotype. While in healthy controls, rates were 96.1 %, 3.9 %, 0 %, respectively. The genotype distribution was also significantly different between T2DM patients and healthy controls (*P* = 0.040).Table 2Allele frequencies and genotype distributions of apoM proximal promoter region in healthy control and T2DM patientsSNP IDAlleleAllele frequencyAlleleGenotypeControl (%)T2DM (%)OR (95 % CI)*P*-valueHealthy control (%frequencies)T2DM (%frequencies)*P*-value of HWE*P*-value111222111222ControlT2DMC-1065AC67.167.81.0300.879363010115121230.3560.2650.878rs805297A32.932.20.701 \~ 1.515(47.4)(39.5)(13.1)(44.4)(46.7)(8.9)T-855CT77.078.01.0330.7914723616280170.2020.1070.801rs9404941C23.022.00.672 \~ 1.588(61.8)(30.3)(7.9)(62.5)(30.9)(6.6)T-778CT86.890.71.4840.162562002124610.1870.3660.146rs805296C13.29.30.851 \~ 2.587(73.7)(26.3)(0)(81.9)(17.8)(0.3)C-724delC98.093.63.379**0.035**73302282920.8610.323**0.040**Del2.06.41.022 \~ 11.176(96.1)(3.9)(0.00)(88.0)(11.2)(0.8)*P*-Value \<0.05 was shown in boldFig. 1Four polymorphic sites, rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C) and C-724del were confirmed in apoM promoter gene. **a**-*b* was a compound heterozygote for C-1065A. **a**-*a*, **a**-*c* were the sequence data of homozygotes for -1065C, -1065A, respectively. Similarly, **b**-*b*, **c**-*b*, **d**-*b* represent the compound heterozygote for T-855C, T-778C, C-724del, respectively. **b**-*a*, **c**-*a*, **d**-*a* were the sequence data of homozygotes for -855T, -778T, -724C, respectively. **b**-*c*, **c**-*c*, **d**-*c* were the sequence data of homozygotes for -855C, -778C, -724del, respectively. The *arrow* presented the mutation site

Correlation between clinical characteristics and SNPs rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C), C-724del in T2DM patients and healthy controls {#Sec10}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Clinical characteristics and lipid levels of T2DM patients and healthy controls in relation to the genotypes of SNPs rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C) and C-724del were showed in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} respectively. In SNP C-724del, the mean TC level was lower in T2DM patients with mutant allele compared to the wide-type homozygotes carriers (*P* = 0.046).Table 3C-724del. Genotype and clinical characteristics of T2DM patients and healthy controlHealthy controlT2DM*P*-valueCCC/- + −/−CCC/- + −/−CC vs. (C/- + −/−) in healthy controlCC vs. (C/- + −/−) in T2DM patientsN (male/femal)40/330/3131/8718/130.2030.949AGE (yrs)52.67 ± 4.9356.54 ± 7.6856.26 ± 11.2456.81 ± 13.140.3920.830SBP (mmHg)110.00 ± 10.00117.81 ± 13.15137.93 ± 20.45136.06 ± 24.200.3140.641DBP (mmHg)74.00 ± 4.0076.00 ± 8.0783.64 ± 11.4081.97 ± 11.440.6720.444DM duration (yrs)6.55 ± 5.876.41 ± 5.610.895HbA1c (%)9.56 ± 2.509.58 ± 2.370.960Cr (umol/L)50.50 ± 9.0365.01 ± 14.6375.13 ± 32.6574.30 ± 24.270.0940.891CYS-C (mg/L)0.86 ± 0.100.98 ± 0.221.18 ± 0.511.15 ± .380.3620.798SOD (U/mL)107.67 ± 15.50106.87 ± 10.2982.63 ± 25.9677.42 ± 24.340.8980.292FPG (mmol/L)5.19 ± 0.335.37 ± 0.379.43 ± 3.359.59 ± 3.220.4090.807TC (mmol/L)4.20 ± 0.164.28 ± 0.524.52 ± 1.254.05 ± .930.779**0.046**TG (mmol/L)0.64 ± 0.111.20 ± 0.412.22 ± 1.951.98 ± 1.35**0.022**0.503HDL-C (mmol/L)1.49 ± 0.111.42 ± 0.191.22 ± 0.311.19 ± 0.370.5600.706LDL-C (mmol/L)2.42 ± 0.072.31 ± 0.412.55 ± 0.802.32 ± 0.740.1250.119ApoA-I (g/L)1.63 ± 0.111.68 ± 0.261.30 ± 0.341.22 ± 0.320.7480.210ApoB (g/L)0.71 ± 0.090.75 ± 0.180.91 ± 0.340.83 ± 0.290.7060.228LP (a) (mg/L)210.37 ± 54.13129.60 ± 115.45157.20 ± 199.35156.10 ± 119.130.2340.976apoM (ng/uL)23.63 ± 8.8024.93 ± 11.7820.44 ± 10.2118.20 ± 8.530.8510.245Data are means ± SD. *P*-Value \<0.05 was shown in boldTable 4C1065A. Genotype and clinical characteristics of T2DM patients and healthy controlHealthy controlT2DM*P*-valueCCCA + AACCCA + AACC vs. (CA + AA) in healthy controlCC vs. (CA + AA) in T2DM patientsN (male/femal)18/1822/1866/4983/610.6630.968AGE (yrs)55.00 ± 8.2457.35 ± 8.8457.50 ± 10.4155.39 ± 12.230.2360.141SBP (mmHg)118.31 ± 13.08116.50 ± 12.62139.84 ± 22.64136.01 ± 19.290.5420.142DBP (mmHg)76.39 ± 8.3875.65 ± 7.3285.13 ± 11.5982.09 ± 11.100.683**0.033**DM duration (yrs)6.32 ± 5.626.71 ± 6.000.600HbA1c (%)9.80 ± 2.519.37 ± 2.450.171Cr (umol/L)66.38 ± 16.0563.39 ± 13.2272.97 ± 30.9076.68 ± 32.380.3760.351CYS-C (mg/L)0.97 ± 0.200.97 ± 0.221.19 ± 0.531.16 ± 0.460.8920.581SOD (U/mL)107.25 ± 10.84106.20 ± 10.6781.30 ± 19.6182.58 ± 29.860.6720.692FPG (mmol/L)5.28 ± 0.385.42 ± 0.339.92 ± 3.559.07 ± 3.100.087**0.041**TC (mmol/L)4.18 ± 0.514.33 ± 0.534.49 ± 1.444.44 ± 1.020.2060.767TG (mmol/L)1.16 ± 0.421.20 ± 0.422.19 ± 1.632.20 ± 2.080.6470.957HDL-C (mmol/L)1.42 ± 0.201.41 ± 0.201.20 ± 0.311.22 ± 0.320.8750.552LDL-C (mmol/L)2.24 ± 0.402.38 ± 0.412.53 ± 0.822.52 ± 0.780.1420.936ApoA-I (g/L)1.64 ± 0.251.68 ± 0.281.27 ± 0.361.32 ± 0.310.5000.240ApoB (g/L)0.72 ± 0.170.77 ± 0.190.89 ± 0.320.91 ± 0.350.2320.597LP (a) (mg/L)117.72 ± 86.94143.92 ± 132.57156.66 ± 231.64157.40 ± 152.600.3170.975apoM (ng/uL)24.34 ± 11.0224.62 ± 11.9619.21 ± 8.4620.93 ± 11.100.9170.171Data are means ± SD. *P*-Value \<0.05 was shown in boldTable 5T855C. Genotype and clinical characteristics of T2DM patients and healthy controlHealthy controlT2DM*P*-valueTTTC + CCTTTC + CCTT vs. (TC + CC) in healthy controlTT vs. (TC + CC) in T2DM patientsN (male/femal)21/2619/1090/7259/380.0770.406AGE (yrs)56.83 ± 9.3755.28 ± 7.1956.12 ± 12.1456.68 ± 10.350.4470.703SBP (mmHg)116.28 ± 13.45119.10 ± 11.64138.06 ± 20.66137.13 ± 21.370.3530.732DBP (mmHg)75.02 ± 7.3777.59 ± 8.3183.54 ± 11.5483.27 ± 11.220.1650.851DM duration (yrs)6.41 ± 5.846.74 ± 5.840.657HbA1c (%)9.61 ± 2.519.48 ± 2.440.663Cr (umol/L)62.20 ± 13.0669.02 ± 16.1774.91 ± 33.7075.23 ± 28.29**0.047**0.938CYS-C (mg/L)0.95 ± 0.210.99 ± 0.211.18 ± 0.501.16 ± 0.480.4180.789SOD (U/mL)106.64 ± 11.45106.79 ± 9.5383.19 ± 29.2680.03 ± 18.550.9520.341FPG (mmol/L)5.35 ± 0.365.36 ± 0.369.42 ± 3.299.50 ± 3.410.9310.858TC (mmol/L)4.35 ± 0.484.12 ± 0.574.55 ± 1.364.32 ± .940.0750.149TG (mmol/L)1.18 ± 0.391.18 ± 0.472.27 ± 2.032.07 ± 1.630.9560.409HDL-C (mmol/L)1.42 ± 0.191.41 ± 0.221.21 ± 0.321.22 ± 0.310.9400.810LDL-C (mmol/L)2.40 ± 0.372.18 ± 0.432.56 ± 0.832.47 ± 0.74**0.023**0.370ApoA-I (g/L)1.67 ± 0.261.64 ± 0.281.30 ± 0.341.28 ± 0.340.6400.713ApoB (g/L)0.76 ± 0.180.72 ± 0.190.94 ± 0.370.85 ± 0.270.334**0.034**LP (a) (mg/L)154.47 ± 128.7094.30 ± 69.74161.87 ± 219.55149.06 ± 132.16**0.023**0.603apoM (ng/uL)26.63 ± 11.9221.02 ± 9.8720.55 ± 10.5519.53 ± 9.13**0.037**0.427Data are means ± SD. *P*-Value \<0.05 was shown in boldTable 6T778C. Genotype and clinical characteristics of T2DM patients and healthy controlHealthy controlT2DM*P*-valueTTTC + CCTTTC + CCTT vs. (TC + CC) in healthy controlTT vs. (TC + CC) in T2DM patientsN (male/femal)29/2711/9131/9718/130.8050.949AGE (yrs)55.21 ± 8.7659.10 ± 7.5756.12 ± 11.7156.81 ± 13.340.0820.764SBP (mmHg)118.73 ± 12.32113.50 ± 13.58136.83 ± 20.59136.06 ± 24.200.1170.851DBP (mmHg)76.57 ± 8.2374.40 ± 6.3483.11 ± 11.2081.97 ± 11.440.2880.598DM duration (yrs)6.49 ± 5.816.41 ± 5.610.943HbA1c (%)9.51 ± 2.489.58 ± 2.370.875Cr (umol/L)64.42 ± 13.4665.88 ± 17.7876.19 ± 33.3774.30 ± 24.270.7050.761CYS-C (mg/L)0.96 ± 0.190.98 ± 0.271.19 ± 0.531.15 ± .380.7380.730SOD (U/mL)106.93 ± 10.18106.05 ± 12.2880.89 ± 20.9777.42 ± 24.340.7550.401FPG (mmol/L)5.38 ± 0.375.28 ± 0.329.43 ± 3.389.59 ± 3.220.2490.813TC (mmol/L)4.24 ± 0.554.33 ± 0.454.36 ± 0.954.05 ± .930.5250.097TG (mmol/L)1.16 ± 0.411.25 ± 0.452.14 ± 1.601.98 ± 1.350.4010.596HDL-C (mmol/L)1.42 ± 0.201.40 ± 0.181.20 ± 0.311.19 ± 0.370.8060.840LDL-C (mmol/L)2.30 ± 0.412.35 ± 0.412.49 ± 0.762.32 ± 0.740.5960.224ApoA-I (g/L)1.65 ± 0.241.69 ± 0.341.28 ± 0.321.22 ± 0.320.6250.350ApoB (g/L)0.75 ± 0.180.75 ± 0.180.89 ± 0.310.83 ± 0.290.9500.318LP (a) (mg/L)121.14 ± 97.43160.56 ± 148.32160.62 ± 203.15156.10 ± 119.130.1830.904apoM (ng/uL)23.35 ± 10.9127.68 ± 12.5820.05 ± 10.2118.20 ± 8.530.1480.337

Haplotype analyses {#Sec11}
------------------

We estimated all possible haplotypes from the observed genotypes of rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C) and C-724del by SHEsis software online (<http://analysis.bio-x.cn/myAnalysis.php>). The link-age disequilibrium analysis showed no obvious LD between any of two SNPs (Table [7](#Tab7){ref-type="table"}). Haplotype (frequency \> 3 %) derived from the four SNPs of apoM between T2DM and controlss was showed in Table [8](#Tab8){ref-type="table"}. Among these four haplotypes, the haplotype T-T-del (-855-778-724), C-T-del (-1065-778-724) and C-T-del (-1065-855-724) were found to be associated with an increased risk of T2DM (OR = 3.268 95 % CI = 0.977 \~ 10.928; *P* = 0.040, OR = 3.375 95 % CI = 1.021 \~ 11.163; *P* = 0.035 and OR = 3.309 95 % CI = 0.998 \~ 10.978, *P* = 0.039, respectively). The power calculation showed that the study had 78.9 % power to detect differences of C-724del between T2DM and controls subjects at a significance level of 0.05.Table 7Linkage disequilibrium testsHaplotypers9404941rs805296C-724delD'r^2^D'r^2^D'r^2^rs8052970.8920.1090.7490.0300.9950.027rs9404941\--0.9980.0320.7850.010rs805296\-\-\--0.9400.006Table 8Association of apoM promoter haplotypes with T2DMHaplotypeHaplotype frequencyOR (95 % CI)*P*-valueCasesControlsH1-855-778-724T T del0.0610.0193.268 (0.977 \~ 10.928)**0.040**H2-1065-778-724C T del0.0640.0203.375 (1.021 \~ 11.163)**0.035**H3-1065-855-724C T del0.0620.0203.309 (0.998 \~ 10.978)**0.039**Haplotype with frequency less than 3 % was pooled and not analyzed. *P*-Value \<0.05 is shown in bold

Discussion {#Sec12}
==========

In the present study, we performed genetic association analysis on apoM promoter SNPs rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C) and C-724del in 259 T2DM patients and 76 healthy controls from an eastern Han Chinese population. It clearly demonstrated that C-724del polymorphism in the promoter region appeared to increase susceptibility to T2DM. However, the results of this study did not support an association between rs805296 (T-778C) polymorphism and T2DM susceptibility in eastern Han Chinese. Besides that, SNPs rs805297 (C-1065A) and rs9404941 (T-855C) had no significant difference in allele frequencies and genotype distributions between T2DM patients and healthy controls. Lower plasma apoM levels were also seen in T2DM patients than healthy controls in our study just as previous research \[[@CR17]\]. However, the plasma apoM levels were not statistically different in T2DM patients with rs805297 (C-1065A), rs9404941 (T-855C), rs805296 (T-778C) and C-724del mutant allele compared to the wide-type homozygotes carriers respectively. Consistently, the haplotype analysis showed that the haplotype T-T-del (-855-778-724), C-T-del (-1065-778-724) and C-T-del (-1065-855-724) were associated with an increased risk for T2DM.

ApoM was a plasma apolipoprotein which was particularly present in HDL-C and to a lesser extent in TG-rich lipoproteins (TGRLP) and LDL-C \[[@CR1]\]. It was required for prebeta-HDL-C formation and cholesterol efflux to HDL-C \[[@CR7], [@CR18], [@CR19]\]. Besides that, apoM was associated with apoA-I, which was the main apolipoprotein in HDL and might be an independent predictor of apoA-I catabolism in overweight-obese, insulin resistant men \[[@CR20], [@CR21]\]. There were many evidences to suggest the involvement of apoM in the development of T2DM. Xu, et al. found that the apoM expression was reduced in alloxan-diabetic mice models \[[@CR22]\], while Nojiri, et al. recently discovered the opposite result in streptozotocin-induced diabetic mice models \[[@CR23]\]. Similarly, plasma apoM levels were lower in T2DM patients \[[@CR17]\], our study also confirmed this result, so apoM might be a useful serum marker for the identification of T2DM, but the exact reasons were still unknown. ApoM was particularly present in HDL-C particles \[[@CR4]\] and its expression was associated with liver X receptor (LXR) \[[@CR24]\], fork head box A2 (Foxa2) \[[@CR25], [@CR26]\], liver receptor homolog-1 (LRH-1) \[[@CR27]\] hepatic nuclear factor-1α (HNF-1α) \[[@CR28]\], peroxisome proliferator-activated receptor beta/delta/gamma \[[@CR29], [@CR30]\], protein kinase C (PKC) \[[@CR31]\], leptin and insulin \[[@CR23], [@CR32]\] et al., all of which were related to glucose metabolism. Animals and cell culture suggested that hyperglycemia could down-regulate apoM expression \[[@CR33]\]. Moreover, apoM over expression might have a potential role in improving insulin resistance \[[@CR34]\], further explain that modulating apoM expression might against insulin resistance in type 2 diabetes. Plasma levels of apoM were also decreased in maturity-onset diabetes of the young (MODY3) subjects, might attribute to the hepatocyte nuclear factor-1α (HNF-1α)-dependent impairment of apoM expression leaded by heterozygous HNF-1α mutations \[[@CR35], [@CR36]\].

This study found that the frequency of del allele in SNP C-724del were significantly increased in T2DM patients compared with healthy controls. In Zhou' research, they reported that 290 individuals (88.0 %) had the C/C genotype, 18 individuals (5.8 %) had the C/del genotype, 1 individuals (0.3 %) had the del/del genotype and the frequency of del allele was 3.2 % in total 309 eastern Han Chinese controls \[[@CR14]\]. The frequency of del allele were also significantly different between T2DM patients and above healthy controls (*P* = 0.013), both together, demonstrated that SNP C-724del was significantly associated with a higher risk for T2DM. In genetics, SNPs in the promoter region could affect the gene transcription and even protein expression. Zheng et al. found that constructs C-724del in apoM promoter region showed significant decreased promoter activity \[[@CR14], [@CR15]\]. That the expression of apoM was lower while the frequency of C-724del mutant allele in T2DM patients was higher compared with those healthy controls, suggested that this polymorphisms, in promoter region, might contribute to the down-regulation of apoM expression. Unfortunately, the lowing of plasma apoM levels of -C724del mutant allele carriers compared to the wide-type homozygotes carriers in T2DM patients was not statistically different (18.20 ± 8.53 ng/uL vs 20.44 ± 10.21 ng/uL, *P* = 0.245) in present study, so further researchs were needed by enlarging the sample.

ApoM SNP rs805396 (T-778C) was strongly associated with T1DM in both Han and Swedish populations, demonstrated that allele C of apoM SNP rs805396 (T-778C) may increase promoter activity and confer the risk susceptibility to the development of T1DM \[[@CR9]\]. Moreover, apoM SNP rs805396 (T-778C) was also strongly associated with T2DM in Han \[[@CR10]\], showed that apoM SNP rs805396 (T-778C) might be involved in the common pathogenesis of both T1DM and T2DM. It would have been ideal if the previous found that the SNP rs805296 (T-778C) were associated with T2DM in northern China were reproduced in this eastern Han Chinese. Unfortunately, the allele frequencies and genotype distributions between T2DM patients and healthy controls were not statistically different in this study just as previous research in Hong Kong Chinese population \[[@CR11]\], the possible reason might be the difference in genotype of SNPs in different area of china \[[@CR12], [@CR13]\]. In addition, SNPs rs805297 (C-1065A) and rs9404941 (T-855C) had no significant difference in allele frequencies and genotype distributions between T2DM patients and healthy controls just as previous report \[[@CR10]\]. It should be mentioned that the result of the present study needs further replications in other areas and races to avoid spurious associations which are common in genetic association researchs.

Conclusions {#Sec13}
===========

In conclusion, the polymorphism C-724del in the promoter region of the apoM gene could confer the risk of T2DM among eastern Han Chinese. Unfortunately, the lowing of plasma apoM levels of C-724del mutant allele carriers compared to the wide-type homozygotes carriers in T2DM patients was not statistically different in present study, so further researchs were needed by enlarging the sample.
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